Navigating key news stories in pharma

Featured Stories

Featured
A Strategic Lever: The New Role for CDMOs in the Innovative Age
Future Biopharma
A Strategic Lever: The New Role for CDMOs in the Innovative Age
Future Biopharma

Bio/pharma companies are adjusting their strategies to cope with a variety of industry trends and are seeking out partners that can not only provide them with capacity but also support them through their innovation journey.

Read More →
Future Biopharma
News
CPHI Frankfurt 2025: Scaling 3D Printing and Taking a Global Approach to Supply Chain Security
Future Biopharma
CPHI Frankfurt 2025: Scaling 3D Printing and Taking a Global Approach to Supply Chain Security
Future Biopharma

While widespread adoption of 3D printing within the bio/pharma industry needs to overcome some key hurdles, its potential for the future is tremendous, emphasizes Tom Sellig from Adare Pharma Solutions.

Future Biopharma
CPHI Frankfurt 2025: The Central Role of India in Building a Resilient Supply Chain
Future Biopharma
CPHI Frankfurt 2025: The Central Role of India in Building a Resilient Supply Chain
Future Biopharma

Bio/pharma companies are turning their focus to Indian CDMOs to build resilience into their KSM and API supply chains and to help with complex payloads, according to Yann D’Hervé from Cohance.

Future Biopharma
Nanoform Establishes New Company and Outlicenses Nanoformulation of Encorafenib
Dealmaking
Nanoform Establishes New Company and Outlicenses Nanoformulation of Encorafenib
Dealmaking

In collaboration with A.forall and IMGA, Nanoform has formed a new subsidiary aimed at outlicensing Nanoencorafenib as an attractive patient-centric lifecycle management opportunity or value-added generic medicine opportunity.

Dealmaking

Dealmaking

Featured
Nanoform Establishes New Company and Outlicenses Nanoformulation of Encorafenib
Nanoform Establishes New Company and Outlicenses Nanoformulation of Encorafenib

In collaboration with A.forall and IMGA, Nanoform has formed a new subsidiary aimed at outlicensing Nanoencorafenib as an attractive patient-centric lifecycle management opportunity or value-added generic medicine opportunity.

BMS to Acquire Orbital and Strengthen Cell Therapy Portfolio
BMS to Acquire Orbital and Strengthen Cell Therapy Portfolio

The companies have entered into a definitive agreement for the acquisition, which includes an investigational immunotherapy preclinical candidate and a proprietary RNA modular platform.

Praxis Makes Strategic Acquisition of ACI
Praxis Makes Strategic Acquisition of ACI

Through the purchase the contract packaging organization will add 160,000 sq. ft. of manufacturing and warehouse facilities in Florida and will expand its capabilities and market segments.

Monte Rosa, Novartis Target ‘Undruggable’ Proteins in Major Immunology Partnership
Monte Rosa, Novartis Target ‘Undruggable’ Proteins in Major Immunology Partnership

A deal worth up to USD 5.7 billion has been unveiled that is aimed at the development of molecular glue degraders for immune-mediated diseases utilizing Monte Rosa’s AI-driven QuEEN platform.

Future Biopharma

Featured
CPHI Frankfurt 2025: Scaling 3D Printing and Taking a Global Approach to Supply Chain Security
CPHI Frankfurt 2025: Scaling 3D Printing and Taking a Global Approach to Supply Chain Security

While widespread adoption of 3D printing within the bio/pharma industry needs to overcome some key hurdles, its potential for the future is tremendous, emphasizes Tom Sellig from Adare Pharma Solutions.

CPHI Frankfurt 2025: The Central Role of India in Building a Resilient Supply Chain
CPHI Frankfurt 2025: The Central Role of India in Building a Resilient Supply Chain

Bio/pharma companies are turning their focus to Indian CDMOs to build resilience into their KSM and API supply chains and to help with complex payloads, according to Yann D’Hervé from Cohance.

A Strategic Lever: The New Role for CDMOs in the Innovative Age
A Strategic Lever: The New Role for CDMOs in the Innovative Age

Bio/pharma companies are adjusting their strategies to cope with a variety of industry trends and are seeking out partners that can not only provide them with capacity but also support them through their innovation journey.

Driving Progress in Biomanufacturing
Driving Progress in Biomanufacturing

As demand for increasingly complex biologics grows, technological advances and innovative approaches are enabling companies to progress their biomanufacturing efforts.
Valsynthese

R&D

Featured
Gene Therapy Improves Hearing in Children with Profound Genetic Hearing Loss
Gene Therapy Improves Hearing in Children with Profound Genetic Hearing Loss

Regeneron’s investigational gene therapy, DB-OTO, has been found to provide meaningful improvements in hearing for nearly all of the participants in the CHORD clinical trial.

Scientists Discover New Class of Antibiotics that Work Against MDR Bacteria
Scientists Discover New Class of Antibiotics that Work Against MDR Bacteria

Led by researchers at the University of Liverpool, a team of international scientists have discovered a new, potent class of antibiotics that will help in the fight against antimicrobial resistance.

Nanoform and Takeda Showcase Advances in Biologic Drug Delivery at DDF Summit
Nanoform and Takeda Showcase Advances in Biologic Drug Delivery at DDF Summit

At the 15th Drug Delivery & Formulation Summit in Boston, Nanoform unveiled proof‑of‑concept data demonstrating new approaches to biologic drug delivery.

Circio Demonstrates Increased AAV Potency with Circular RNA Technology
Circio Demonstrates Increased AAV Potency with Circular RNA Technology

In a financial report webcast, the Norwegian biotech presented breakthrough circVec-AAV data showing up to 40x higher protein expression than traditional mRNA-AAVs.

Expansion

Featured
Lonza Gets Swissmedic Nod for New Aseptic Drug Product Filling Line
Lonza Gets Swissmedic Nod for New Aseptic Drug Product Filling Line

Located in Stein, Switzerland, the new GMP licensed line will enable the company to provide integrated, end-to-end solutions for the whole biologics and bioconjugation value chain.

Terumo Expands CDMO Production Capacity with European Acquisition
Terumo Expands CDMO Production Capacity with European Acquisition

Through the strategic acquisition of a facility from WuXi Biologics based in Germany, Terumo has strengthened its ability to serve both domestic and international pharmaceutical companies.

Enzene Announces Official Inauguration of New U.S. Biomanufacturing Facility
Enzene Announces Official Inauguration of New U.S. Biomanufacturing Facility

Located in Hopewell, N.J., the new facility signifies the first major manufacturing investment for Enzene within the U.S., strengthening the company’s commitment to supporting innovation and supply chain resilience in the country.

Delpharm Set to Transform Boucherville Facility After Securing Government Funding
Delpharm Set to Transform Boucherville Facility After Securing Government Funding

This latest funding will bolster the additional investment and private capital and will allow Delpharm to modernize its Boucherville facility to be able to meet the growing demand for injectable drugs.

Strategy

Featured
AstraZeneca Joins Pfizer in U.S. Drug Pricing Program
AstraZeneca Joins Pfizer in U.S. Drug Pricing Program

The Big Pharma companies have voluntarily agreed to a range of measures to reduce the cost of medicines for American patients while also preserving the biopharmaceutical innovation ecosystem of the U.S.

Rezon Bio Launches as European Biologics CDMO
Rezon Bio Launches as European Biologics CDMO

The Polish company debuts as a European biologics CDMO, offering services from accelerated development through to commercialization using advanced digital tools and mirrored GMP-certified sites.

Responding to Demand with the Latest Service Offerings
Responding to Demand with the Latest Service Offerings

Innovator companies are increasingly engaging with outsourcing partners in efforts to improve cost and time efficiencies across the complete drug development lifecycle.

GSK Names CEO Designate as Emma Walmsley Set to Step Down
GSK Names CEO Designate as Emma Walmsley Set to Step Down

Luke Miels, the company’s current Chief Commercial Officer, has been appointed as the new CEO, signaling the company’s next phase after Dame Emma Walmsley’s era of strategic growth and innovation.

Regulatory

Featured
Staying Ahead of Regulatory Revisions
Staying Ahead of Regulatory Revisions

In light of the evolving therapeutic landscape, increasing use of advanced technologies, and political shifts, regulatory updates are inevitable, meaning that bio/pharma companies will need to adjust quickly to new requirements.

Intercept Withdraws Liver Disease Drug from U.S. Market
Intercept Withdraws Liver Disease Drug from U.S. Market

The company has decided to voluntarily withdraw obeticholic acid from the U.S. market after the FDA issued a request for the withdrawal and put a clinical hold on trials involving the drug.  

Viatris’ Generic Iron Sucrose Gains FDA Nod
Viatris’ Generic Iron Sucrose Gains FDA Nod

FDA has granted approval to Viatris for its generic intravenous iron replacement product as a treatment of iron deficiency anemia in adult and pediatric patients with chronic kidney disease.

FDA Accepts GSK’s Gepotidacin for Priority Review
FDA Accepts GSK’s Gepotidacin for Priority Review

If the oral antibiotic gains regulatory approval, patients who are 12 years of age and older in the U.S. suffering from urogenital gonorrhea will have an alternative, non-invasive treatment option.

Upcoming Events

Featured
ELRIG Drug Discovery 2025

ELRIG’s Drug Discovery 2025 is again hosted by the city of Liverpool and as Europe’s leading drug discovery and life sciences conference will have scientific tracks covering topics including robotics, cell and disease models, ‘omics, AI, oncology and neurodegenerative disease.

ADC Process Development Summit 2025

Returning to Boston this October, the 3rd ADC Process Development Summit is the only meeting dedicated to the technical and strategic challenges of ADC process development. In an intimate setting, join 80+ experts from AstraZeneca, Merck, Gilead, Genentech, AbbVie, and more for two days of focused insights, real-world case studies, and peer-led discussion to revolutionize your antibody-drug conjugate manufacturing process.

CDMO Leadership Awards 2025 Europe

For more than a decade, the CDMO Leadership Awards have recognized contract development and manufacturing organizations (CDMOs) worldwide for outstanding quality, capabilities, expertise, reliability, and service. In 2025, the awards make their European debut at CPHI Frankfurt, providing a dedicated stage to celebrate excellence across the region.